Drug facts
MoleculeAprepitant (Emend)
Generics already compete: 3 makers on the market. 9 A-rated products from 3 makers substitute at the counter.
Emend was first approved by the FDA on 03/26/2003 under NDA 021549; the application holder is Merck Sharp and Dohme LLC.
The latest NADAC for APREPITANT 80 MG CAPSULE is $78.69 per unit (as of 10/28/2026).
Holder Merck Sharp and Dohme LLCApplication NDA 021549Approved 03/26/2003
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
330days until the latest Emend patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved03/26/2003
Last patent09/26/2027
2004200820122016202020242028
- Latest patent
- 09/26/2027Emend Orange Book
- Later patents, other products
- Aponvie 09/18/2035; Cinvanti 09/18/2035 Orange Book
02Competition
- Generics
- 3 generic makers Orange Book
- Staged generics
- 1 passed FDA review, awaiting market entry FDA
- First generic approved
- 09/24/2012 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Aprepitant profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $78.69 per unitAPREPITANT 80 MG CAPSULE, mid-priced of 3 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 12/12/2025Class II, Aprepitant, Merck Sharp & Dohme LLC FDA enforcement
04Product
- Application holder
- Merck Sharp and Dohme LLC Orange Book
- Application
- NDA 021549 Orange Book
- First approved
- 03/26/2003 Orange Book
- Dosage forms
- capsule; emulsion
- Routes
- intravenous, oral
- Other brand names
- AponvieCinvanti
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.